ORTHO Regenerative Technologies is a cutting-edge med tech firm that uses its proprietary RESTORE technology platform to dramatically improve the success rate of orthopedic and sports medicine surgeries.
- In layman’s terms, that means company has a wonder delivery platform that delivers biologics – drugs made from biological processes – to repair soft tissues in the human body.
The technology uses biologics derived from things like plasma and bone marrow concentrate to regenerate new tissue in various musculoskeletal conditions.
- This includes Wound Healing, Cartilage repair and Osteo-arthritis
So, how big is the market opportunity for Soft Tissue Repair? At least $5bn in the U.S. alone. This includes:
Rotator Cuff TEAR (which leads to shoulder dysfunction and pain):
- 4m patients in the U.S. alone
- 600,000 annual surgeries in the U.S. alone
- $600m+ market opportunity
Meniscus Tear Repair (which is painful and compromises knee function):
- There are 1.2m surgeries annually in U.S. alone
- $1bn+ market opportunity
Cartilage Lesions Repair (this is where lesions cause friction and pain):
- 1.2m detected lesions annually in U.S. alone
- 120,000 surgeries and a lack of options
- $1bn+ market opportunity
Get comfy for this insightful interview with Claude LeDuc, Ortho’s CEO.
Tags: biologics, CSE, Meniscus Tear Repair, orthopedic, otc, Rotator Cuff TEAR, stocks, tsx, tsx-v